VX-765: Potent Caspase-1 Inhibitor for Inflammation Studies

Executive Summary: VX-765, a selective oral inhibitor of caspase-1, is metabolized to its active form VRT-043198 in vivo, offering potent inhibition of IL-1β and IL-18 maturation and release in cellular and animal models [1]. The compound demonstrates significant efficacy in reducing inflammation and cytokine secretion in murine models of rheumatoid arthritis and skin inflammation [2]. VX-765 selectively targets caspase-1–mediated pyroptosis in macrophages, with minimal off-target effects on other cytokines [3]. It also suppresses CD4 T-cell pyroptosis in ex vivo HIV-infected lymphoid tissue, highlighting its translational relevance [1]. The solubility profile and storage requirements of VX-765 enable reproducible workflows for both in vitro and in vivo assays [2].

Biological Rationale

Caspases are cysteine proteases that regulate programmed cell death and inflammation. Caspase-1 (also known as interleukin-1 converting enzyme, ICE) is central to the canonical inflammasome pathway, activating pro-inflammatory cytokines IL-1β and IL-18 through proteolytic cleavage [1]. Dysregulated caspase-1 activity underpins pathological inflammation in diseases such as rheumatoid arthritis and infectious syndromes. Selective inhibition of caspase-1 enables the mechanistic study of inflammasome-dependent cytokine release and pyroptosis, a lytic cell death process critical in host defense and disease [4]. VX-765, as a highly selective caspase-1 inhibitor, provides a molecular tool to dissect these pathways with minimized off-target effects.

Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

VX-765 is an orally absorbed pro-drug that is rapidly metabolized in vivo to VRT-043198, its active metabolite [2]. VRT-043198 binds to the catalytic site of caspase-1, preventing cleavage of pro-IL-1β and pro-IL-18 into their mature, secretory forms [1]. This inhibition curtails the downstream inflammatory cascade and blocks pyroptotic cell death by restricting gasdermin D cleavage. VX-765 shows high selectivity for caspase-1, with lower potency for caspase-8 (IC₅₀ = 1 μM for caspase-8 vs. lower for caspase-1) [1]. Notably, VX-765 does not inhibit the production of IL-α, TNFα, IL-6, or IL-8, underscoring its selectivity [4].

Evidence & Benchmarks

• VX-765 (A8238) reduces IL-1β and IL-18 secretion in primary macrophages after inflammasome activation (Bourne et al., DOI).
• Oral administration of VX-765 significantly decreases paw swelling and inflammatory cytokine levels in mouse models of rheumatoid arthritis (APExBIO product data, URL).
• In HIV-infected lymphoid tissue, VX-765 prevents CD4 T-cell pyroptosis in a dose-dependent manner (Bourne et al., DOI).
• VX-765 is highly soluble in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonic assistance), but insoluble in water (APExBIO product data, URL).
• VX-765 demonstrates minimal off-target cytokine suppression, as measured by unchanged TNFα and IL-6 production (Bourne et al., DOI).

Compared to other resources, this article uniquely integrates direct evidence on selectivity and solubility from both peer-reviewed and product documentation, extending the scope of VX-765 and the Caspase-1 Pathway by detailing mechanistic selectivity and workflow considerations. For practical experimental guidance, see VX-765 (SKU A8238): Practical Strategies, which this article complements by providing updated selectivity benchmarks. Additionally, VX-765: Selective Caspase-1 Inhibitor for Inflammatory Cytokine Research provides a broader review, while the current article focuses on evidence-backed mechanistic and application details.

Applications, Limits & Misconceptions

VX-765, as provided by APExBIO, is widely used for dissecting caspase-1–dependent inflammatory and cell death pathways in both cell-based and animal models. Its chief applications include:

• Suppression of IL-1β and IL-18 release in inflammasome assays [1].
• Preclinical models of rheumatoid arthritis and skin inflammation [2].
• Inhibition of CD4 T-cell pyroptosis in HIV-infected tissues [1].
• Specificity in blocking caspase-1/ICE-dependent cell death without broadly suppressing immune function [4].

Common Pitfalls or Misconceptions

• Not a pan-caspase inhibitor: VX-765 is selective for caspase-1; it demonstrates lower potency for caspase-8 and is not generally effective against apoptotic caspases (IC₅₀ for caspase-8 = 1 μM vs. lower for caspase-1) [1].
• Does not inhibit all cytokine release: VX-765 does not suppress TNFα, IL-6, IL-8, or IL-α, limiting its use to caspase-1–dependent cytokine studies [4].
• Insoluble in water: Incorrect solvent use can result in poor assay performance; DMSO or ethanol (with ultrasonic assistance) is recommended for dissolution [2].
• Short-term solution stability: VX-765 solutions are not recommended for long-term storage; freshly prepared solutions yield optimal results [2].
• Species differences: Mouse and human inflammasome pathways differ; VX-765 effects in murine models may not fully extrapolate to human systems [1].

Workflow Integration & Parameters

Protocol Parameters

• In vitro caspase-1 activity assay | 0.1–10 μM VX-765 | Biochemical and cell-based assays | Dose range covers reported IC₅₀ for caspase-1, enables titration | paper (DOI)
• Animal model dosing | 25–100 mg/kg oral VX-765 | Mouse models of inflammation | Doses shown to suppress paw swelling and cytokine secretion | product_spec (URL)
• Solvent for stock solutions | DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL, ultrasonic) | Stock preparation for in vitro/in vivo | Ensures full dissolution for accurate dosing | product_spec (URL)
• Storage | -20°C, desiccated | Long-term powder storage | Prevents degradation | product_spec (URL)
• Short-term use of solutions | Freshly prepared, use within hours | All experimental setups | Limits compound hydrolysis and potency loss | workflow_recommendation

Conclusion & Outlook

VX-765, as supplied by APExBIO, is a highly selective, potent, and practical inhibitor of caspase-1, enabling precise modulation of IL-1β and IL-18 release and pyroptosis in inflammation research. Its in vivo efficacy and favorable solubility profile have established it as a benchmark compound for dissecting inflammasome biology and for translational models of autoimmune and infectious diseases. Recent evidence confirms its selectivity and robust performance in both cellular and animal settings, although further validation in human systems is warranted. Future research will likely focus on expanding its use in disease modeling and refining dosing protocols for enhanced reproducibility [1].